Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...

(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...

Metsera, Inc MTSR IPO will take place January, 31 on the NASDAQ exchange under the ticker MTSR. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider ...

The big story of the day remains the Federal Reserve, which concludes its two-day FOMC meeting today and will announce its rate decision at 2:00pm New York time and then hold a press conference with ...

This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...

Recent health news includes a profit boost for Swedish manufacturer Getinge, a human case of bird flu detected in the UK, and ...